The Journal of venomous animals and toxins including tropical diseases · 2023 · 28 citations · 79 references
PharmacyImmunologyPharmacokineticsAntibody EngineeringDrug DiscoveryImmunotherapyAntivenom TherapyPharmacokinetics Of Monoclonal AntibodiesSnake EnvenomationTherapeutic Antibody DevelopmentTherapeutic Monoclonal AntibodiesVenom BiologyAntibody-mediated Toxin NeutralizationAntivenom NeutralizationAntivenom PharmacokineticsAntivenom ReactionsSnake Venom ToxicologySnakebite Envenomation ManagementSnakebite ToxicologyTreatment Protocols For Snakebite
Snakebite envenoming is a significant global health challenge, and for over a century, traditional plasma-derived antivenoms from hyperimmunized animals have been the primary treatment against this infliction. However, these antivenoms have several inherent limitations, including the risk of causing adverse reactions when administered to patients, batch-to-batch variation, and high production costs. To address these issues and improve treatment outcomes, the development of new types of antivenoms is crucial. During this development, key aspects such as improved clinical efficacy, enhanced safety profiles, and greater affordability should be in focus. To achieve these goals, modern biotechnological methods can be applied to the discovery and development of therapeutic agents that can neutralize medically important toxins from multiple snake species. This review highlights some of these agents, including monoclonal antibodies, nanobodies, and selected small molecules, that can achieve broad toxin neutralization, have favorable safety profiles, and can be produced on a large scale with standardized manufacturing processes. Considering the inherent strengths and limitations related to the pharmacokinetics of these different agents, a combination of them might be beneficial in the development of new types of antivenom products with improved therapeutic properties. While the implementation of new therapies requires time, it is foreseeable that the application of biotechnological advancements represents a promising trajectory toward the development of improved therapies for snakebite envenoming. As research and development continue to advance, these new products could emerge as the mainstay treatment in the future.
79
Melody Cobleigh, Charles L. Vogel, Debu Tripathy et al. · Journal of Clinical Oncology · 1999 · 2.8K citations
Medicine, Oncology, Pharmacology +17
Anuradhani Kasturiratne, A.R. Wickremasinghe, Nilanthi de Silva et al. · PLoS Medicine · 2008 · 1.9K citations · Full text
Public Health, Health Sciences, Population Health Sciences +16
Single‐domain antibody fragments with high conformational stability
Mireille Dumoulin, Katja Conrath, Annemie Van Meirhaeghe et al. · Protein Science · 2002 · 626 citations · Full text
L.B.A. van de Putte, Michel Malaise, J Sany et al. · Annals of the Rheumatic Diseases · 2004 · 620 citations · Full text
Snake Envenoming: A Disease of Poverty
Robert A. Harrison, Adam D Hargreaves, Simon C. Wagstaff et al. · PLoS neglected tropical diseases · 2009 · 610 citations · Full text